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Abstract
Nicotinamide phosphoribosyltransferase (Nampt) inhibitors such as FK866 are potent inhibitors of NAD
+ synthesis that show
promise for the treatment of different forms of cancer. Based on Nampt upregulation in activated T lymphocytes and on
preliminary reports of lymphopenia in FK866 treated patients, we have investigated FK866 for its capacity to interfere with T
lymphocyte function and survival. Intracellular pyridine nucleotides, ATP, mitochondrial function, viability, proliferation,
activation markers and cytokine secretion were assessed in resting and in activated human T lymphocytes. In addition, we
used experimental autoimmune encephalomyelitis (EAE) as a model of T-cell mediated autoimmune disease to assess FK866
efficacy in vivo. We show that activated, but not resting, T lymphocytes undergo massive NAD
+ depletion upon FK866-
mediated Nampt inhibition. As a consequence, impaired proliferation, reduced IFN-c and TNF-a production, and finally
autophagic cell demise result. We demonstrate that upregulation of the NAD
+-degrading enzyme poly-(ADP-ribose)-
polymerase (PARP) by activated T cells enhances their susceptibility to NAD
+ depletion. In addition, we relate defective IFN-c
and TNF-a production in response to FK866 to impaired Sirt6 activity. Finally, we show that FK866 strikingly reduces the
neurological damage and the clinical manifestations of EAE. In conclusion, Nampt inhibitors (and possibly Sirt6 inhibitors)
could be used to modulate T cell-mediated immune responses and thereby be beneficial in immune-mediated disorders.
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Introduction
FK866 (formerly WK175) is a potent inhibitor of nicotinamide
phosphoribosyltrabsferase (Nampt), the key enzyme in the NAD
+
synthesis pathway from Nam [1,2,3]. Initial studies carried out in
cancer cell lines indicated that exposure to FK866 results in a slowly
progressing form of cell death due to intracellular NAD
+ depletion
[1,4]. Following preclinical evaluation in animal models, FK866
underwent clinical experimentations in patients with advanced solid
tumors showing some activity and acceptable toxicity [5]. Subse-
quent studies demonstrated that the activity of FK866 is improved
when the drug is used in combination with ionizing radiations and
withDNAdamagingagentsasthesetreatmentsresultinactivationof
the NAD
+-degrading enzyme poly-(ADP-ribose) polymerase (PARP)
which in turn cooperates to lower NAD
+ levels in the cell [6,7,8].
The preclinical studies and the clinical experimentation
revealed that lymphocytes are probably the normal cell type that
is most sensitive to FK866 since lymphopenia was consistently
observed in response to this drug [5]. In line with these findings,
using a mouse strain lacking Nampt expression in the T and B cell
lineage, Rongavaux and colleagues have recently shown that
Nampt is critically required for the development of both T and B
lymphocytes [9]. Finally, T lymphocytes upregulate Nampt in
response to mitogenic stimuli [10,11,12,13], suggesting that
Nampt activity may be especially required during the process of
T lymphocyte activation.
Here, we evaluated FK866 for its capacity to interfere with T
lymphocyte function and survival and assessed the mechanisms
underlying FK866 efficacy in these cells. We show that Nampt
inhibition with FK866 has catastrophic consequences in activated
PLoS ONE | www.plosone.org 1 November 2009 | Volume 4 | Issue 11 | e7897T cells where it virtually obliterates intracellular NAD
+ stores
leading to functional impairment and ultimately to autophagic cell
demise. In line with these premises, we show that FK866 strikingly
ameliorates the manifestations of experimental autoimmune
encephalomyelitis (EAE), a prototypical model of T-cell mediated
autoimmune disorder. Our data provide the rational for the
evaluation of Nampt inhibitors in immune mediated disorders.
Results
FK866 Prevents T Lymphocyte Proliferation and
Selectively Affects Viability of Activated T Lymphocytes
The capacity of FK866 to interfere with T lymphocyte
responses was initially tested in proliferation assays which
showed how this compound virtually abrogates T cell prolifer-
ation in response to mitogenic stimulation (Figure 1A and data
not shown). Proliferation inhibition was typically accompanied
by morphological changes suggestive of cell demise (data not
shown). Therefore we assessed whether FK866 would affect T
cell viability and whether resting and activated T lymphocytes
would behave differently in terms of susceptibility to this drug.
We found that FK866 was toxic to PBLs when these were
concomitantly activated with mitogens [phytohematoagglutinin-
P (PHA), or concanavalin A (Con A)], while unstimulated cells
were mostly unaffected (Figure 1B). Similarly, activation with
allogeneic DCs also sensitizedP B L st oF K 8 6 6 - i n d u c e dc e l l
demise while unstimulated PBLs were less affected (Figure 1C,
D). As detected after a five-day treatment, FK866-induced cell
d e a t hi na c t i v a t e dP B L sw a sc o n centration dependent, with
EC50s comprised between 1 and 10 nM, and typically reached a
plateau starting from 30 nM (Figure 1B, C). In resting PBLs,
F K 8 6 6E C 5 0w a sn e v e rr e a c h e di nthe concentration range we
used. In experiments where FK866 treatment (33 nM) was
extended for up to 12 days, unstimulated PBLs were still .80%
viable indicating that resting T cells are mostly resistant to
FK866-induced cell death (data not shown). Similarly, FK866
Figure 1. Nampt inhibition with FK866 prevents T lymphocyte proliferation and selectively kills activated T cells. A, PBLs were seeded
in 96-well plates in the presence or absence (unstim.) of PHA and 33 nM FK866. Proliferation was assessed 96 h later by standard [
3H]thymidine
incorporation assay. B, PBLs were incubated in 96-well plates in the presence or absence of 5 mg/ml PHA, 1 mg/ml Con A, with or without the
indicated concentrations of FK866. Five days later viability was detected by PI staining and flow cytometry. Spontanous cell death was 12.2% and
28.1% for PHA- and Con A-stimulated PBLs, respectively. C, D, PBLs were stimulated for 7 days with or without allogeneic mature DCs before FK866 at
the indicated concentrations was added. After 5 days viability was assessed by PI staining and flow cytometric analysis using the lymphocyte gate (C).
Spontaneous PBL death was 18.4%. D: phenotype of unstimulated or DC-stimulated PBLs. E, Immature or LPS stimulated DCs were cultured for 7 days
with 33 nM FK866 before staining with FITC-conjugated Annexin-V and PI and flow cytometry. F, Resting or PHA-stimulated PBLs were treated with
33 nM FK866 for the indicated times and subsequently stained with FITC-conjugated Annexin-V and PI for flow cytometric analysis. Mean values 6
SD of five (B) and three (A, C) different donors are presented. D–F One representative experiment out of three is shown.
doi:10.1371/journal.pone.0007897.g001
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after protracted exposure (Figure 1E and data not shown).
Activated T lymphocyte death in response to FK866 was
typically a slowly progressing form of cell demise as an increase
in the rate of dead T lymphocytes was normally observed starting
from 72 h treatment (Figure 1F).
CD3-neg PB mononuclear cells (PBMCs) were less than 20% of
the PBL preparations and this percentage further decreased on
exposure to T cell mitogens or to allogeneic DCs (,10%)
(Figure 1D and data not shown). In order to exclude that T
lymphocyte death induced by FK866 was mediated by the
contaminating PBMCs, we performed similar experiments using
highly pure CD3
+ cells isolated by magnetic cell sorting (.95%).
These tests reproduced the results shown in Figure 1B–C,
confirming that FK866 primarily targets activated T lymphocytes
(data not shown).
Activated PBLs Undergo Massive NAD(H) Depletion
following Nampt Inhibition
We next sought to determine whether the increased toxicity of
Nampt inhibition in activated as compared to resting PBLs would
reflect a different response to the drug in terms of intracellular
levels of pyridine nucleotides. Intracellular NAD(H) and
NADP(H) were measured by cycling enzymatic assays, whereas
ATP levels were determined by HPLC. In resting PBLs, the mean
NAD
+, NADH, NADP
+, and NADPH intracellular amounts were
88615 pmoles/10
6 cells, 12.360.5 pmole/10
6 cells, 4.260.7
pmoles/10
6 cells, and 21.760.7 pmoles/10
6 cells, respectively. In
mitogen-stimulated PBLs, the mean NAD
+,N A D H ,N A D P
+,a n d
NADPH levels were 295.665.9 pmoles/10
6 cells, 60.962.1
pmoles/10
6 cells, 7.160.7 pmoles/10
6 cells, and 94.665.6
pmoles/10
6 cells, respectively. The absolute values of pyridine
nucleotides concentrations and their increased content in
mitogen-stimulated PBLs are in line with those detected in
previous studies [14]. Treatment with FK866 significantly
reduced intracellular NAD
+ levels in both resting and activated
T lymphocytes (Figure 2A). However, while unstimulated PBLs
retained on average about 20% of their intracellular NAD
+
content when exposed to 33 nM FK866 (range 11.8%–32%), in
mitogen-stimulated T lymphocytes FK866 typically reduced
intracellular NAD
+ to less than 5% of the levels in FK866-
untreated cells (range 0.6–7.4%). In activated PBLs treated with
FK866, both the absolute NAD
+ amount and the percentage of
NAD
+ content relative to FK866-untreated controls were
significantly lower than those detected in resting PBLs
(Figure 2B). NADH levels closely paralleled NAD
+ levels in
response to FK866 (Figure 2C). Vice versa, NADP
+ and particularly
NADPH levels were depleted by FK866 to a much lesser extent.
Thus, Nampt inhibition appears to primarily affect the NAD(H)
pool in T lymphocytes. Figure 2D shows a time course experiment
where intracellular NAD
+ and ATP level, and cell viability were
monitored simultaneously in activated PBLs treated with FK866.
As i g n i f i c a n tN A D
+ decrease was detected as early as 3 h after
addition of FK866 (Figure 2D). This was followed by a decrease in
intracellular ATP, which became apparent between 12 and 24 h
after drug addition. Finally, a decrease in cell viability was
detected 72 h after onset of FK866 treatment. These data indicate
that T lymphocyte death due to Nampt inhibition is preceded by a
period of several hours when cells are viable despite very low
NAD
+ levels and decreasing ATP content. Exogenously added
NAD
+ completely rescued FK866-induced PBL death confirming
that the effect of FK866 on PBLs viability is indeed a consequence
of NAD
+-shortage (Figure 2E).
PARP and Sirtuin Activity Predispose Activated T
Lymphocytes to Intracellular NAD
+ Depletion
DNA-damaging agents leading to PARP activation were
previously shown to increase FK866 activity [6,7]. In activated
T lymphocytes, a marked increase in PARP activity occurs to
ensure efficient DNA repair and possibly to implement signal
transduction [10,15,16]. Therefore, we assessed whether PARP is
involved in conferring susceptibility to FK866 to activated T cells.
We first verified by quantitative PCR (Q-PCR) (Figure 3A) and by
Western blotting (not shown) that PARP1 and Nampt become
upregulated in PBLs in response to mitogenic stimulation. Three
structurally unrelated PARP inhibitors, NU1025, 3-AB, and PJ34
indeed provided a partial rescue of intracellular NAD
+ levels upon
treatment of activated PBLs with FK866 (Figure 3B). This effect
was paralleled by an increase in cell viability (Figure 3C). NU1025,
3-AB, and PJ34 had no effect on T lymphocyte proliferation in
response to mitogens (data not shown). Thus, the protection
conferred by these compounds against FK866-induced cell demise
is not attributable to inhibition of T lymphocyte activation. In line
with a recent report [4], we found that several T cell leukemia cell
lines are highly susceptible to FK866 (not shown). In Jurkat cells,
NU1025, 3-AB, and PJ34 alleviated FK866-induced NAD
+
depletion (Fig. 3D) and virtually completely prevented cell death
induced by low FK866 concentrations (,500 pM) in a concen-
tration dependent fashion (Figure 3E). However, similarly to what
observed in primary PBLs, at higher FK866 concentrations the
protection conferred by PARP inhibitors to Jurkat cells and to
other T cell leukemia cell lines was only partial (not shown).
The fact that PARP inhibitors only partially block FK866-
induced NAD
+ shortage and cell death in activated T cells suggests
that other enzymatic activities/metabolic processes could come into
play to enhance susceptibility to FK866. The ADP-ribosyl cyclase
CD38 is also upregulated in T cells by activation stimuli [17]. The
possible contribution of CD38 to the enhanced sensitivity of
activated T lymphocytes to FK866 was first assessed by transfecting
Jurkat cells with CD38-specific small interfering RNAs, in the
presence or absence of FK866. CD38 silencing did not induce any
significant effects on NAD
+ levels and on viability (data not shown).
Moreover, we did not observe a difference in the sensitivity to
FK866 between HeLa cells transfected with sense-(CD38
+) or with
anti-sense-(CD38
2) human CD38 (data not shown) [18].
Finally, sirtuins also use NAD
+as a substrate [19], and some ofthese
enzymes may undergo upregulation in activated T lymphocytes (see
below). We found that the sirtuin inhibitor sirtinol induced a slight,
although significant increase in the levels of intracellular NAD
+ in
activated T cells exposed to FK866 (data not shown). Consistently,
sirtinol mitigated FK866-induced cell death in activated PBLs
(Figure 3F). Thus, sirtuin activity appears to also be among the factors
involved in conferring susceptibility to FK866 to activated T cells.
NAD
+ Depletion Induces T Lymphocyte Death via
Mitochondria Dysfunction and Autophagy
Mitochondrial oxidative phosphorylation is the cellular major
ATP source under aerobic conditions. NADH is required for
mitochondrial transmembrane potential (DYm) maintenance
which in turn is a prerequisite for ATP generation [20]. We
found that in primary activated PBLs as well as in T cell leukemia
cell lines DYm is dissipated following FK866-induced NAD
+
depletion (Figure 4A and data not shown). DYm loss due to Nampt
inhibition was more pronounced in activated than in resting PBLs
(Figure 4B). To demonstrate that DYm loss is causally involved in
FK866-mediated cell death we made use of Jurkat cells engineered
to overexpress Bcl2 as this antiapoptotic protein maintains DYm in
NAD
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+ efflux
(Figure 4C) [21,22]. Indeed, Bcl2-overexpression protected Jurkat
cells from FK866-mediated mitochondrial depolarization
(Figure 4C). This effect was not due to interference by Bcl2 on
intracellular NAD
+ depletion as FK866 efficiently depleted
intracellular NAD
+ also in Bcl2-overexpressing Jurkat (data not
shown). Consistent with the fact that DYm is maintained by Bcl2
overexpression irrespective of NAD
+ shortage, Bcl2 Jurkat cells did
Figure 2. Activated T cells undergo massive NAD
+ depletion upon Nampt inhibition. A, 3610
6 PBLs/well were stimulated (or not, unstim.)
with 5 mg/ml PHA, 1 mg/ml con A, or 50 ng/ml PMA and 0.5 mM ionomycin in the presence or absence of the indicated FK866 concentrations. 48 h
later, cells were lysed in 0.6 M PCA and NAD
+ content was measured in neutralized extracts. NAD
+ levels were normalized to those detected in the
absence of FK866. B, Unstimulated or PHA-stimulated PBLs were treated with 33 nM FK866 for 48 h before NAD
+ content was determined. Absolute
NAD
+ levels are presented. *: p,0.05. C, PBLs were cultured for 48 h with PHA with or without FK866 (33 nM) addition. Subsequently, pyridine
dinucleotides levels were measured in acid (NAD
+ and NAPD
+) or alkaline (NADH and NADPH) cell extracts. Dinucleotide levels were normalized to
those detected without FK866. D, PBLs were incubated with PHA and 33 nM FK866 for the indicated times. Thereafter cells were harvested and NAD
+
and ATP levels were determined in cell extracts whereas cell viability was assessed by PI-staining and flow cytometry. Results were normalized to the
values of FK866-untreated cells. E, Resting or PHA-stimulated PBLs were treated (or not) with 33 nM FK866 in the presence or absence of 1 mM NAD
+.
After five-days viability was assessed determining PI
2 cells by flow cytometry. Results are means 6 SD of five (A) or three (B–E) experiments.
doi:10.1371/journal.pone.0007897.g002
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Thus, ATP reduction in response to NAD
+ depletion is due to
DYm loss. Finally, Bcl2-overexpressing Jurkat cells were virtually
completely resistant to FK866-induced cell death (Figure 4E).
ATP depletion triggers autophagy [23]. To determine the role
of autophagy in cell death caused by FK866 we made use of 3-MA
and LY294002 two class III phosphoinisitide-3 phosphate kinase
(PI3K) inhibitors known to block autophagy [24]. Both inhibitors
reduced FK866-induced cell demise in PBLs (Figure 4F, G) as well
as in Jurkat cells and in the T cell leukemia cell line H9 (data not
shown). No protection from FK866 was conferred by the mitogen-
activated protein kinase inhibitor PD098059 or by the NF-kB
inhibitor BAY 11–7082 (data not shown). PI3K inhibition in
activated PBLs had no effect on PARP upregulation in response to
PHA (not shown), ruling out that the PI3K inhibitors may interfere
with FK866-induced cell death by affecting PARP. Therefore, in
line with previous studies [4,25], FK866 induces autophagic cell
death in activated T lymphocytes.
Since mitochondria dysfunction is also a trigger of the intrinsic
apoptotic pathway [26], we assessed whether this mechanism would
also contribute to FK866 cytotoxicity. Indeed, we detected released
cytochrome cin the cytosolicfraction of FK866 treated T lymphocytes
(not shown). However, the pan-caspase inhibitor zVAD-fmk, the
caspase-9 inhibitor Z-LE(OMe)HD(OMe)-FMK, as well as the
caspase-8 inhibitor Z-IE(OMe)TD(OMe)-FMK failed to protect from
FK866-induced cell death (data not shown). Thus, although
associated with cytochrome c cytosolic relocalization, cell demise via
NAD
+ depletion appears to occur in a caspase-independent fashion.
Figure 3. PARP inhibitors and sirtinol attenuate FK866-induced T cell demise. A, PBLs were cultured for 24 h with or without PHA.
Thereafter, Nampt and PARP1 levels were detected by Q-PCR. mRNA levels in PHA-stimulated cells were compared to those in unstimulated PBLs. B,
Resting or PHA-stimulated PBLs were incubated with or without 33 nM FK866 in the presence or absence of 300 mM NU1025, 10 mM PJ34, or 300 mM
3-AB. 48 h later NAD
+ levels were assessed (presented as % of values in FK866-untreated PBLs). *, p,0.05. C, PHA-stimulated PBLs were incubated for
five days with or without 33 nM FK866 in the presence or absence of 300 mM NU1025, 10 mM PJ34, or 300 mM 3-AB. Thereafter, viability was assessed.
D, 5610
5 Jurkat cells were treated for two days with 500 pM FK866 in the presence or absence of 300 mM NU1025, 5 mM PJ34, or 300 mM 3-AB.
Subsequently, NAD
+ content was determined and expressed as % of values in FK866-untreated Jurkat. E, 3610
4 Jurkat cells/well were incubated in
96-well plates with or without 300 pM FK866 in the presence or absence of the indicated concentrations of NU1025, PJ34, or 3-AB. Viability was
determined 96 h later by PI cell staining and flow cytometry. F, PBLs were incubated for five days with PHA, with or without 33 nM FK866, in the
presence or absence of 30 mM sirtinol. Viability was subsequently assessed by PI staining and flow cytometry. C, E, F, each treatment was tested in
triplicate wells. Results are presented as means 6 SD of three experiments.
doi:10.1371/journal.pone.0007897.g003
NAD
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+ Shortage and Lymphocyte
Death Induced by Nampt Inhibition
We performed experiments to evaluate whether FK866-induced
NAD
+ depletion and cell death in PBLs would be prevented by
Nam and by Na. Nam is known to act as an antidote for FK866
and recent studies showed that this effect may be due to direct
competition for the binding site on the enzyme [1,2]. Conversely,
Na supplementation rescues NAD
+ synthesis in cells that express
Na phosphoribosyltransferase (Naprt1) and can thereby synthesize
NAD
+ via the Preiss-Handler pathway [1,27]. Nam raised
intracellular NAD
+ levels to over 150% of the untreated control
in both FK866-treated and untreated cells (Figure 5A). We verified
Naprt1 expression in human PBLs by Q-PCR. Moreover, we
found that Naprt1 mRNA is upregulated in activated T cells, with
the extent of the upregulation varying depending on the stimulus
used (Figure 5B). Na per se did not affect intracellular NAD
+ levels.
However, it partially prevented NAD
+ depletion upon treatment
with FK866, to about 50% of the pyridine dinucleotide content in
untreated T lymphocytes (Figure 5A). Both Nam and Na
efficiently countered PBL death in the presence of cytotoxic
FK866 concentrations (Figure 5C) and over a wide range of
FK866 concentrations (Figure 5D). However, the potency of Nam
and Na as FK866 antagonists was different: Na protected PBLs
from 33 nM FK866-induced cell death with an EC50 of 10
26 M
(Figure 5E, and data not shown) compared to an EC50 value for
Nam of 3610
25 M. No protection from FK866-induced cell death
was conferred to PBLs by tryptophan supplementation indicating
that the de novo NAD
+ synthesis pathway is not a relevant source
Figure 4. Nampt inhibition with FK866 induces mitochondria depolarization and ATP depletion in activated T lymphocytes. A, PHA-
stimulated PBLs were incubated with 33 nM FK866 and DYm was determined at the indicated days of exposure. B, Resting of PHA-stimulated PBLs
were cultured with 33 nM FK866 for five days. Thereafter PBLs with conserved DYm-high were quantified by flow-cytometry. C, Bcl2-overexpressing
Jurkat and the respective vector control cells were incubated with 10 nM FK866 for the indicated number of days. Thereafter, DYm was determined.
Inset, Western blot for Bcl2 and c-tubulin expression. D, 5610
5 Bcl2-overexpressing Jurkat and the vector control cells were incubated with or
without 10 nM FK866 for the indicated times before ATP was detected. ATP levels are presented as % of ATP in FK866-untreated cells. E, 3610
4 Bcl2-
overexpressing and control Jurkat cells/well were incubated in 96-well plates with or without the indicated FK866 concentrations. Viability was
determined by PI staining and flow cytometry 96 h later. F, PHA-stimulated PBLs were incubated in the presence or absence of 33 nM FK866 with or
without the indicated concentrations of 3-MA. Viability was detected after five days. *, p,0.05. G, PBLs incubated in 96-well plates in the presence of
5 mg/ml PHA were treated for five days with the indicated FK866 concentrations in the presence or absence of 20 mM LY294002. Viability was
subsequently determined by PI staining and flow cytometry. B, Results are presented as means 6 SD of three experiments (B, D–G). Panels A and C
are representative of three separate experiments.
doi:10.1371/journal.pone.0007897.g004
NAD
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+ in human T cells [27]. Finally, Nam and Na did not
exert their protective effects by interfering with the process of T
lymphocyte activation, since proliferation (Figure 5F) and
activation markers (CD25, HLA-DR, not shown) were normally
induced in PBLs by PHA regardless of the presence of these
metabolites.
These findings are consistent with the occurrence of the Preiss-
Handler pathway of NAD
+ biosynthesis in PBLs, although its
contribution to replenish the NAD
+ pool upon FK866 treatment
seems to be limited (see Discussion).
NAD
+ Shortage Prevents IFN-c Production by Activated T
Lymphocytes
Nampt inhibition and the consequent NAD
+ shortage were
previously shown to negatively affect secretion of IL-1b, IL-6 and
TNF-a in macrophages and dendritic cells [28,29]. Thus, we
performed experiments to determine whether NAD
+ depletion via
FK866 wouldalsoaffectcytokinesecretioninT lymphocytes.These
experiments were performed within 48 h from FK866 addition
when T cell viability was still unaffected to be able to detect
functional changes and avoid the interference of autophagic cell
destruction. In this time frame, FK866 had no effect on the
upregulation of activation markers such as CD25 and HLA-DR in
mitogen-stimulated PBLs (Figure 6A). However, intracellular
cytokine staining revealed that FK866 strongly reduced the number
of TNF-a-producing CD3
+ T cells and virtually abrogated IFN-c
synthesis (Figure 6A). These results were confirmed by direct
measurement of TNF-a and IFN-c in the PBL supernatants
(Figure 6B). Addition of Na, which replenishes intracellular NAD
+
stores but does not inhibit sirtuin activity (see below) [30], fully
restored IFN-c synthesis by PBLs (Figure 6C) demonstrating that
IFN-c downregulation was due to NAD
+ depletion.
Figure 5. Nam and Na prevent NAD
+ shortage and cell death induced by FK866 in human T lymphocytes. A, PHA-stimulated PBLs were
treated (or not) with 33 nM FK866 in the presence or absence of 10 mM Nam or of 10 mM Na. After 48 h, NAD
+ content was determined (expressed as
percentage of NAD
+ content in FK866-untreated cells). B, PBLs were cultured for 24 h with or without PHA, 1 mg/ml Con A, or 50 ng/ml PMA and
0.5 mM ionomycin. Thereafter, Naprt1 mRNA levels were detected by Q-PCR. mRNA levels in mitogen-stimulated PBLs were compared to those in
unstimulated PBLs. C, D, PHA-stimulated PBLs were incubated for five days with or without 10 mM Nam or 10 mM Na in the presence or absence of
the indicated FK866 concentrations. Thereafter, cells were imaged by light microscopy (C), and cell viability was determined (D). E, PHA-stimulated
PBLs were incubated for five days with or without 33 nM Fk866 in the presence of the indicated concentrations of Nam, Na, or tryptophan (Trp).
Viability was subsequently determined. F, PBLs were stimulated with or without PHA in the presence or absence of 1 mM Nam or Na. Thymidine
incorporation was measured after 48 h by a 16-h pulse with 0.5 mCi/well [
3H]thymidine. D-F each treatment was tested in triplicate wells. Results are
means 6 SD of three (A, B, F) or four (D, E) experiments. In panel C, one representative experiment out of three is shown.
doi:10.1371/journal.pone.0007897.g005
NAD
+ in T Lymphocyte Function
PLoS ONE | www.plosone.org 7 November 2009 | Volume 4 | Issue 11 | e7897Defective TNF-a synthesis as a consequence of NAD
+ shortage
was attributed to reduced function of the NAD
+-dependent
sirtuin Sirt6 [29]. Interestingly, Sirt6-deficient animals develop
profound lymphopenia as a result of a cell non-autonomous
mechanism, suggesting a possible defect of relevant cytokines or
growth factors involved in T cell function [31]. Thus, we
evaluated whether IFN-c secretion inhibition may depend on
reduced Sirt6 activity. Indeed, two structurally unrelated sirtuin
inhibitors, sirtinol and Nam, prevented IFN-c expression in T
cells as shown by intracellular cytokine staining and IFN-c
detection in the supernatants (Figure 6D, E) confirming a
putativerolefor asirtuin member inIFN-c synthesis.Conversely,
the PARP inhibitor PJ34 did not affect IFN-c production
(Figure 6E).
When evaluating Sirt6 levels in T lymphocytes, we found that
Sirt6 transcription is induced by mitogenic stimulation (Figure 7A).
To assess the role of Sirt6 in IFN-c and TNF-a production by T
cells we expressed a validated Sirt6 shRNA (S6 sh2) in Jurkat and
H9 cells by retroviral transgenesis [32]. Indeed, S6 sh2 effectively
downregulated Sirt6 mRNA and protein as shown in Jurkat cells
(Figure 7B, C). No detrimental effect of Sirt6 silencing on cell
viability was observed (data not shown). Jurkat cells with reduced
Sirt6 levels showed reduced IFN-c and TNF-a production on
stimulation with mitogens (Figure 7D, E). Conversely, IL-4
secretion was not affected by Sirt6 deficiency (Figure 7F). Sirt6
silencing led to reduced intracellular IFN-c levels in H9 cells
stimulated with a mitogen cocktail (Figure 7G). Finally, spleno-
cytes from Sirt6 knockout mice were found to secrete less IFN-c
Figure 6. Intracellular NAD
+ depletion prevents TNF-a and IFN-c production by activated T lymphocytes. A, B, 5610
6 PBLs were
stimulated with 5 mg/ml PHA with or without 33 nM FK866 for 36 h and subsequently incubated with 50 ng/ml PMA and 0.5 mM ionomycin for
further 5 h. Thereafter, HLA-DR and CD25 expression were detected by flow cytometry. TNF-a and IFN-c content was determined by intracellular
cytokine staining and flow cytometry (A). Released TNF-a and IFN-c were measured by ELISA (B). DMSO and FK866-treated cells were 84% and 83%
viable, respectively. C, 5610
6 PBLs were stimulated with PHA and PMA/ionomycin as above, or left unstimulated. Where indicated, 33 nM FK866 with
or without 10 mM Na was added. Released IFN-c was measured by ELISA. Unstimulated PBLs treated with DMSO or FK866 were 96.3% and 96.5%
viable, respectively. PBLs stimulated with PHA/PMA/ionomycin and treated with DMSO or FK866 were 89% and 89.5% viable, respectively. PBLs
stimulated with PHA/PMA/ionomycin/Na and treated with DMSO or FK866 were 88% and 87% viable, respectively. D, PBLs were stimulated with PHA
and PMA/ionomycin as describe for panel A. Where indicated 10 mM Nam or 50 mM sirtinol were added. Thereafter, cells were harvested and
intracellular IFN-c content was determined by flow cytometry. E, PBLs were stimulated with PHA and PMA/ionomycin as above in the presence or
absence of 10 mM Nam, 50 mM sirtinol, or 10 mM PJ34. 42 h later, the supernatants were collected and IFN-c levels were detected by ELISA. Results
are means 6 SD of four experiments (B, C, E). Panels A and D are representative of four separate experiments.
doi:10.1371/journal.pone.0007897.g006
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altogether these data are consistent with an involvement of Sirt6 in
IFN-c synthesis.
FK866 Reduces Demyelination and Disease Severity in
EAE
Given the capacity of FK866 to interfere with survival of
activated T cell and with the release of immunogenic cytokines, we
sought to determine whether FK866 treatment might be
advantageous in a prototypical autoimmune disease such as
EAE, particularly after disease onset. FK866 was administered at
10 mg/Kg body weight twice daily starting 12 days post MOG-
immunization of the mice, for a total of 10 days. Mononuclear
cells from FK866-treated animals exhibited a significant decrease
in the levels of intracellular pyridine dinucleotides (Figure 8A). As
observed with human PBLs, NAD
+ and NADH were more
severely reduced as compared to NADP
+ and NADPH. FK866
strikingly reduced the clinical disease score as described in
Materials and Methods when compared with vehicle-alone treated
controls, reaching statistical significance from day 19 onward
(Figure 8B, and Table 1). The benefit of FK866 was fully retained
until day 80 from immunization (not shown). The clinical effect of
FK866 was associated with a marked reduction of demyelination
in the spinal cord of treated mice (Figure 8C, and Table 1). FK866
showed no evident toxicity on renal and liver function, nor did
FK866-treated mice show weight loss or increased frequency of
Figure 7. Evidence for an involvement of Sirt6 in IFN-c synthesis. A, PBLs were cultured for 24 h with or without PHA. Thereafter, Sirt6 levels
were detected by Q-PCR. mRNA levels in PHA-stimulated cells were compared to those in unstimulated PBLs. B, C, Jurkat cells were transduced with
PRS, (PRS) GFP-sh, or (PRS) S6 sh2, subsequently, Sirt6 mRNA levels or Sirt6 protein levels were determined by Q-PCR (B) and immunoblotting (C). D–F,
Jurkat cells transduced with PRS or S6 sh2 were stimulated for 12 h with 5 mg/ml PHA, 50 ng/ml PMA, and 0.5 mM ionomycin. Thereafter,
supernatants were harvested and TNF-a (D), IFN-c (E), and IL-4 (F) levels were determined by ELISA. G, H9 cells transduced with GFP-sh or S6 sh2 were
stimulated for 12 h with 5 mg/ml PHA, 50 ng/ml PMA, and 0.5 mM ionomycin. Thereafter, intracellular IFN-c was detected by intracellular staining.
Mean fluorescence intensity for IFN-c expression is indicated for each histogram. H, 3610
6 splenocytes from wild type or Sirt6 KO mice/well were
seeded in 24 well plates and stimulated for 24 h with 1 mg/ml Con A. Thereafter, supernatants were harvested and IFN-c levels were determined by
ELISA. *: p,0.05. Results are means 6 SD of three experiments (A, B, D–F). Panel C and G are representative of three separate experiments.
doi:10.1371/journal.pone.0007897.g007
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days. Hence, FK866 is effective in treating EAE after disease onset
in the absence of obvious toxicity.
Discussion
In this study, we show that activated T lymphocytes are
crucially dependent on Nampt activity for their function and
survival as they face massive NAD
+ depletion and cell demise
when this enzyme is obstructed with FK866. Thus, increased
susceptibility to NAD
+ lowering drugs emerges as a property of
activated T lymphocytes that is susceptible of being targeted
pharmacologically. The consequences of Nampt inhibition in
unstimulated T lymphocytes appear to be less deleterious as these
retain NAD(H) levels that are sufficient to ensure survival in the
majority of the cells.
The high susceptibility of activated T cells to FK866 is due, at
least in part, to PARP upregulation which per se leads to
intracellular NAD
+ reduction, an occurrence normally prevented
by Nampt [8,10,12,16]. The involvement of other enzymatic
activities/metabolic processes in enhancing T cell susceptibility to
FK866 is suggested by the fact that PARP inhibitors only partially
protect activated T lymphocytes from FK866. Experiments aimed
to assess the role of the ADP-ribosyl cyclase CD38 in conferring
susceptibility to FK866 failed to detect major such effects of this
enzyme. Conversely, a partial protection from FK866 was
conferred to activated T cells by the sirtuin inhibitor sirtinol.
Which one(s) of the sirtuin is (are) most active in T cells, and which
role they play has to be defined yet. Nonetheless, our findings
suggest that sirtuins may be responsible for consuming significant
amounts of NAD
+ in T lymphocytes. In addition, sirtuin levels/
activity may increase in response to activation stimuli, as is the case
of Sirt6, which we found to be upregulated in response to
mitogens. Finally, since a 5–13-fold increase in NAD
+ kinase
activity was detected in mitogen-stimulated T lymphocytes [10],
another mechanism contributing to the exhaustion of the NAD(H)
Figure 8. FK866 ameliorates EAE. 10 mg/kg body weight FK866 were administered to mice from day 12 after rMOG immunization for 10 days. A,
NAD(H) and NADP(H) levels were measured in mononuclear cells isolated from spleen and lymph nodes of treated or untreated animals at day 16.
Dinucleotide levels in FK866-treated mice were expressed as % of those detected in control animals. B, FK866 halts EAE severity compared with
controls (p,0.05 from day 19 onward). Arrows indicate the days of FK866 administration. C, Luxol fast Blue staining of the spinal cord shows areas of
demyelination in control mice compared with FK866-treated animals.
doi:10.1371/journal.pone.0007897.g008
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+ into
the NADP(H) pool by the sequential action of NAD
+ kinase and
glucose-6-phosphate dehydrogenase [33]. In line with this
hypothesis is the finding that NADPH levels are virtually
unaffected by FK866 in activated T cells while NAD
+ and NADH
virtually disappear. Why other immune cell types are not affected
by FK866 as much as activated T lymphocytes are remains a
speculative matter. Its is conceivable that the enzymatic activities
that actively consume NAD
+ and that we found upregulated in
activated T cells may not be as much represented in other immune
cells. Alternatively, other cells of the immune system may obtain
their NAD
+ supplies (also) through metabolic pathways that are
not affected by FK866. For instance, it is well documented that
activated DCs upregulate indoleamine 2, 3-dioxygenase (IDO), a
key enzyme in the NAD
+ synthesis pathway from tryptophan
[27,34].
T lymphocyte death due to NAD
+ exhaustion involves DYm
dissipation, ATP shortage, and autophagy. Previous studies
suggested that FK866 induces apoptosis via cytochrome c release
and caspase-9 activation [3]. In FK866-treated T lymphocytes, we
did detect released cytochrome c in the cytosol (not shown).
However, different caspase inhibitors failed to protect activated T
lymphocytes from FK866 cytotoxicity. Thus, T cell death via
FK866, although accompanied by cytochrome c release, is
caspase-independent and is therefore not a classical apoptotic
process.
In addition to the Nam salvage pathway, NAD
+ synthesis from
Na is apparently also an option for T lymphocytes. Previous
studies found that Naprt1 activity is present in human PBLs [14].
We confirmed Naprt1 expression in human PBLs by Q-PCR and
showed that this enzyme undergoes upregulation upon cell
stimulation with mitogens. Consistently, we found that Na
supplementation rescues NAD
+ levels when Nampt is inhibited
allowing for T lymphocyte survival. The fact that FK866 induces
lymphopenia in patients indicates that, under normal conditions,
sufficient Na levels are not available to rescue T lymphocytes in vivo
[5]. On the other hand, the consequences of Nampt inhibition
could theoretically be rescued by increasing dietary Na intake or
by pharmacological Na administration [27]. The expression in T
lymphocytes of other enzymatic activities involved in NAD
+
synthesis from NR and NaR remains unexplored and could
provide insights into possible ways to modulate FK866 immuno-
suppressive activity and/or into mechanisms of resistance to this
drug by cancer cells.
Not only NAD
+ shortage has deleterious repercussions on T cell
viability. Before dying, T lymphocytes experience a phase of
functional impairment where cytokine secretion is prohibited. In
addition to reducing TNF-a production as described previously
[28,29], we found that FK866 also abolishes IFN-c expression.
Importantly, in analogy to TNF-a [29], our data are consistent
with an involvement of Sirt6 also in IFN-c synthesis, since RNAi-
mediated Sirt6 removal reduces the expression of this cytokine.
Moreover, splenocytes from Sirt6 KO mice were found to secrete
less IFN-c than cells from wild type mice do. How Sirt6 is involved
in TNF-a and IFN-c production remains to be determined.
Nonetheless, taken together, these observations depict the Nampt-
Sirt6 axis as an important regulatory pathway for cytokines
involved in inflammation and cell-mediated immunity, that could
be blocked with FK866 or, possibly, with Sirt6 inhibitors (Figure 9).
Based on these findings, we administered FK866 with the aim of
curing EAE, a prototypical T cell-mediated autoimmune disease.
Indeed, administration of FK866 after EAE onset successfully
ameliorated the severity of disease. The clinical efficacy was
demonstrated by a decreased cumulative disease score and by a
consistent reduction in demyelination. Our data with FK866 in
EAE are in line with recent reports of an anti-inflammatory
activity of this drug in carrageenan-induced arthritis [28]. In fact,
we cannot exclude that the benefit of FK866 on the clinical and
histological manifestations of EAE may derive, at least in part,
from effects that are unrelated to its activity on T cells. For
instance, FK866 could (also) alleviate EAE by inhibiting TNF-a
secretion by macrophages and microglia, thereby reducing
inflammation and thus preventing neurological damage [28,29].
In conclusion, Nampt upregulation during T cell activation
appears as an essential adaptation ensuring that sufficient NAD
+
levels are available for metabolic reactions as well as for NAD
+-
utilizing enzymes involved in DNA repair, signal transduction, and
cytokine production. Targeting this metabolic pathway could
represent a novel strategy to selectively eliminate activated T cells
and block detrimental immune/inflammatory reactions such as
those underlying autoimmune diseases, graft-versus-host disease,
and transplant rejection.
Table1. Clinical-pathologic features of EAE-affected mice treated with FK866.
Disease incidence no./no.
total (%)
Disease onset, day after
immunization
Mean maximum
neurologic score Cumulative disease score Demyelination score
Control 16/16 (100%) 10.560.9 2.460.9 53.9623.6 10.664.6
FK866 16/16 (100%) 10.360.9 1.960.8 37.7622.4* 8.163.6*
*p,0.05 (Mann-Whitney test).
doi:10.1371/journal.pone.0007897.t001
Figure 9. A putative model of Nampt’s role in activated T
lymphocytes. Nampt activity is responsible for providing sufficient
NAD
+ supplies during T cell activation. NAD
+, in turn, is required for ATP
synthesis, metabolic reactions, and to replenish NADPH levels. In
addition, NAD
+ represents the substrate of NAD
+-degrading enzymes
such as PARP, CD38, and the sirtuins. Among these, Sirt6 appears to
have a central role in IFN-c and TNF-a production. Nampt inhibitors
such as FK866 (and possibly Sirt6 inhibitors) could be used to modulate
T cell-mediated immune responses and thereby be beneficial in
immune disorders.
doi:10.1371/journal.pone.0007897.g009
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Cell Lines and Reagents
The T cell leukemia cell lines Jurkat, H9, PEER, and Phoenix
were obtained from ATCC (LGC Standards s.r.l. Milan, Italy).
Cells were grown in RPMI 1640-based medium supplemented
with 10% FBS and antibiotics. The Bcl-2 overexpressing Jurkat
cells and the respective vector control cells were a gift of Dr. Claus
Belka (Department of Radiation Oncology, University of Tuebin-
gen, Tuebingen, Germany) [22]. HeLa cells transfected with the
sense (CD38
+) and antisense (CD38
2) cDNA for human full-
length CD38 were obtained and cultured as described [18].
Phytohematoagglutinin-P (PHA), concanavalin A (Con A),
ionomycin, PMA, Nam, Na, Trp, 3-methyladenine (3-MA),
sirtinol, LY294002, NU1025, 3-AB, PJ34, lipopolysaccharide
(LPS), BAY 11–7082, PD098059, and tetramethyl rhodamine
ethyl ester (TMRE) were all obtained from Sigma-Aldrich (Sigma
Aldrich Italia, Milano, Italy). FK866 was generously provided by
the NIMH Chemical Synthesis and Drug Supply Program.
Peripheral Blood Lymphocyte (PBL), NK Cell, and
Dendritic Cell (DC) Isolation
Peripheral blood mononuclear cells (PBMCs) were isolated from
blood samples obtained from healthy donors by Ficoll Hypaque
density gradient centrifugation. 10
7 mononuclear cells/well were
plated in 6-well plates for 2 h in X-VIVO 20 medium (Bio-
Whittaker, Lonza, Milan, Italy) to allow monocytes to adhere.
Non-adhering mononuclear cells (.80% CD3+ lymphocytes,
PBLs) were harvested by washing with phosphate-buffered saline
(PBS, Invitrogen Italia, Milan, Italy). For DC generation, adhering
monocytes were cultured in RPMI 1640 medium supplemented
with 10% FBS and antibiotics in the presence of 100 ng/ml GM-
CSF and 20 ng/ml IL-4 (R&D Systems, Wiesbaden, Germany)
[35]. Where indicated, 100 ng/ml LPS were added to induce DC
maturation. DC phenotype was confirmed by monitoring CD1a,
CD83, HLA-DR, CD80, CD86 and CD14 levels by flow
cytometry. NK cells were isolated as described elsewhere [36].
Immunostaining
Cells were stained using FITC- or PE-conjugated mouse mAbs
against CD3, CD25, HLA-DR (BD) and mouse IgG isotype
control and analysed using a FACSCalibur (Becton Dickinson
Italia, Milan, Italy). For intracellular TNF-a and IFN-c staining,
cells were initially stained with a mouse monoclonal anti-CD3
(FITC- or PE-conjugated). Thereafter, cells were washed and
incubated with 0.25% saponin and a FITC-conjugated anti-
human IFN-c or a PE-conjugated anti-human TNF-a (both from
Becton Dickinson). Finally, cells were washed and analysed by flow
cytometry.
Viability Assays
2.5610
5 PBLs/well were plated in 96 well plates in the presence
or absence of the indicated stimuli. Viability was determined
120 h later by propidium iodide (PI) staining and flow cytometry
(FACS Calibur, Becton Dickinson, BD Italia, Milan, Italy) within
the lymphocyte gate. Viability was calculated with the following
formula: 100-[(experimental death-spontaneous death)/(100-
spontaneous death)x100]. When DCs were used as a stimulator,
2.5610
5 PBLs/well were plated in 96 well plates with 2.5610
4
irradiated (3000 rad) allogeneic DCs. FK866 was added at the
indicated concentrations 7 days later. For Annexin-V/PI staining,
3610
6 PBLs/well were plated in 1 ml medium in 24-well plates in
the presence or absence of 5 mg/ml PHA and treated with 33 nM
FK866 for the indicated amounts of time. Afterwards, cells were
washed, stained with Annexin-V-FITC (Becton Dickinson) and PI
and analyzed by flow cytometry.
Light Microscopy
Cells were imaged at room temperature using the 406
magnification of a Zeiss AXIOVERT200 microscope, camera
Qlympus C-4040ZOOM. The image files were acquired with the
software Olympus CAMEDIA Master 2.5, and subsequently
processed using Microsoft Photo Editor.
Proliferation Assay
PBLs were seeded at 2610
5 per well in 96-well plates.
Proliferation was induced by adding PHA (5 mg/ml) and measured
after 72 h by a 16-h pulse with [
3H]thymidine (0.5 mCi/well;
Amersham Life Science; Buckingham, U.K.).
Mitochondrial Transmembrane Potential (DYm)
Determination
DYm was determined as previously described [37].
ELISA for Detection of IFN-c and TNF-a
Supernatants harvested on day 2 from PBLs cultured in the
presence of the indicated stimuli were analysed for the content of
either IFN-c or TNF-a by ELISA kits from Peprotech Inc.
(Princeton Business Park, Rocky Hill, NJ) according to manufac-
turer’s instructions. IFN-c secretion by splenocytes isolated from
wild type and Sirt6 KO mice (16-days old) [31] was detected using a
sandwich ELISA kit purchased from R&D Systems Inc.
(Minneapolis, MN USA). Data are referred to a standard curve
obtained with recombinant IFN-c or TNF-a, respectively.
Determination of the Intracellular NAD(H), NADP(H) and
ATP Levels
PBLs, resting or activated, were cultured in the presence or
absence of FK866: cells were harvested and lysed with 0.6 M
perchloric acid (PCA) or 0.1 M NaOH, to determine the content
of NAD
+ or NADH, and NADP
+ or NADPH, respectively. The
alkaline extracts were incubated at 70uC for 10 min. Both acid
and alkaline extracts were neutralized and the intracellular content
of the various coenzymes was assessed with a sensitive enzyme
cyclic assay, which exploits the use of alcohol dehydrogenase or of
G6PD, to determine NAD(H) [38], or NADP(H) [39], respective-
ly. To evaluate the content of ATP, cells were lysed in PCA and
the neutralized extracts were analyzed by HPLC [40]. NAD(H)
and NADP(H) levels in murine mononuclear cells (MNCs) isolated
from mice treated (or not) with FK866, were determined as in
human PBLs. NAD(H), NADP(H), and ATP values were
normalized to protein concentrations (micro-BCA kit, Pierce).
siRNA Transfection
Jurkat cells were transfected using the Nucleofector System
(Amaxa GmbH, Cologne, Germany), without (control), or with
StealthTM duplex short interference RNA (siRNA) targeting
CD38. Cells were transfected in parallel with StealthTM Negative
Control. After transfection, cells were incubated in the presence or
absence of FK866 and intracellular NAD+ content was evaluated
as described above. To confirm CD38 silencing, CD38 mRNA
was detected by quantitative real-time PCR.
Retroviral Transgenesis
Empty pRETROSuper (PRS) and PRS GFP-sh were from Dr.
Thijn Brummelkamp (Whitehead Institute for Biomedical Re-
search, Cambridge, Ma, USA); PRS S6 sh2 was from Dr. Katrin
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Medicine, Stanford, CA 94305, USA) [32]. Phoenix cells were
plated in 4 ml medium in 6 cm-dishes and allowed to adhere for
24 h. Thereafter, cells were transfected with 4 mg plasmid DNA
using Transit 293 (Mirus Bio, Madison, WI, USA) according to
the manufacturer’s instructions. The viral supernatant was
harvested 36 and 48 h later and used to infect Jurkat and H9
cells in 24-well plates in the presence of 5 mg/ml protamine sulfate.
Successfully infected cells were selected using 1 mg/ml puromycin.
Q-PCR
Total RNA was extracted from 5610
5 cells using RNeasy kit
reagents (Qiagen, Qiagen Italia, Milan, Italy). Total RNA (1 mg)
was reverse transcribed using random hexamers in a final volume
of 50 ml. 5 ml of the resulting cDNA was used for Q-PCR using a
TaqMan 7900 HT Fast Real TimeAB [41]. Pre-designed primers
and probes for Nampt, PARP1, CD38, Naprt1, and 18S were
obtained from Applied Biosystems. Gene expression was normal-
ized to housekeeping gene expression (18S). Comparisons in gene
expression were done using the 2
2DDCt method [42].
EAE Induction and Treatment Protocol with FK866
This study was performed in compliance with the US
Department of Health and Human Services Guide for the Care
and Use of Laboratory Animals and approved by the Internal
Review Board of the Advanced Biotechnology Center (ABC) in
Genoa, Italy. Female C57BL/6J mice, 6 to 8 weeks old, were
purchased from Harlan Italy (S. Pietro al Natisone, Italy). EAE
was induced by MOG35–55 immunization according to a
previously published protocol [43]. Mice received two intraperi-
toneal injections daily of 10 mg FK866/kg body weight or DMSO
dissolved in 0.5 ml PBS from day 12 through 16, and from day 19
through 23. Groups of 16 mice for each treatment (FK866 vs.
DMSO) were used. Weight and clinical score were recorded daily.
Clinical scores were assigned according to a standard and
validated 0 to 5 scale [43]. Unless moribund, mice were followed
for at least 40 days following immunization. Disease incidence,
onset, and maximum score were recorded for each mouse and
expressed as mean +/2SD. The cumulative disease score was
calculated by summing the neurologic scores recorded daily for
each mouse along the whole period of observation.
Histology
Euthanized mice were transcardially perfused with 4%
paraformaldehyde before spinal cords were collected and
embedded in paraffin. 5-mm sections were stained with hematox-
ylin and eosin for detection of inflammatory infiltrates while Luxol
fast Blue was used to observe myelin. All sections were analyzed
with an Olimpus Provis AX70 (Olimpus Italia, Segrate, Milan,
Italy) optical microscope. The areas of spinal cord demyelination
were identified on individual images and traced manually on the
composite images. Their surface was determined with Image Pro-
PLUS 4 software (Media Cyberbetics, Silver Spring, MD) and
expressed as a percentage of the total surface area. All histological
evaluations were performed in a blind fashion.
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